A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
13 citations
,
July 2010 in “Drug safety” Lamotrigine may cause hair loss, affecting treatment compliance and health.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
2 citations
,
July 2018 in “Journal of pediatric epilepsy” A teenager lost hair after starting epilepsy medication levetiracetam.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2018 in “Hair transplant forum international” Naltrexone shows promise as a safe treatment for a type of hair loss called lichen planopilaris.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
78 citations
,
June 2005 in “Annals of oncology” Cetuximab can cause excessive eyelash growth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
1 citations
,
May 2021 in “Scientific Reports” Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
October 2025 in “Journal of Drug Delivery Science and Technology” Resveratrol-loaded carriers may help reduce hair loss from chemotherapy when used with scalp cooling.
11 citations
,
August 2010 in “Pediatric dermatology” Tacalcitol cream effectively and safely treated a rare skin condition called Lichen Spinulosus in two cases.
18 citations
,
May 2020 in “Biomolecules” Spironolactone, a heart and liver drug, has new uses including cancer treatment, viral infection prevention, and skin condition improvement.
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
February 2025 in “FASEB BioAdvances” Verteporfin reduces growth and stem cell traits in rat hair follicle cells by blocking the Hippo pathway.
April 2025 in “Scientific Reports” Astragaloside A may help fight lung cancer by targeting specific proteins.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
8 citations
,
June 2016 in “Journal of Pharmacy Practice” Lisinopril, a heart medication, probably caused hair loss in a patient, which stopped after switching drugs.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
5 citations
,
April 2016 in “PubMed” Cetuximab often causes skin problems, but they can be managed without stopping treatment.
November 2025 in “Cancer Management and Research” Targeting Keratin 17 may help overcome cancer therapy resistance.